

10/510119
DT04 Rec'd PCT/PTO 04 OCT 2004

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claims 1-12. (Cancelled)

Claim 13 (new): A method for treating a tumor or infectious agent in a subject, wherein an effective amount of an agonistic anti-CD40 antibody, or a fragment thereof which stimulates the CD40 receptor is administered to the subject for induction of systemic T cell immunity against an antigen of the tumor or infectious agent, and wherein the treatment does not comprise immunization with an antigen of the tumor or infectious agent.

Claim 14 (new): The method according to claim 13, wherein the tumor or infectious agent does not express the CD40 receptor.

Claim 15 (new): The method according to claim 13, wherein the CD40 receptor targeted by the agonistic anti-CD40 antibody or fragment thereof which stimulates the CD40 receptor is expressed on dendritic cells of the treated subject.

Claim 16 (new): The method according to claim 13, wherein the induced systemic T cell immunity is a cytotoxic T cell response.

Claim 17 (new): The method according to claim 13, wherein the agonistic anti-CD40 antibody or fragment thereof is human, humanized, chimeric or deimmunized.

Claim 18 (new): The method according to claim 13, wherein the fragment is a V_H, V_L, Fv, Fd, Fab, (Fab)₂ or scFv fragment of a human antibody.

Claim 19 (new): The method according to claim 13, wherein the agonistic anti-CD40 antibody, or a fragment thereof which stimulates the CD40 receptor is administered to the subject by injection or oral administration.

Claim 20 (new): The method according to claim 17, wherein the human, humanized, chimeric or deimmunized agonistic anti-CD40 antibody is administered to the subject by injection or oral administration.

Claim 21 (new): The method according to claim 18, wherein the V_H, V_L, Fv, Fd, Fab, (Fab)₂ or scFv fragment of the human antibody agonistic anti-CD40 antibody is administered to the subject by injection or oral administration.

Claim 22 (new): The method according to claim 19, wherein the injection is an intra-tumoral injection.

Claim 23 (new): The method according to claim 20, wherein the injection is an intra-tumoral injection.

Claim 24 (new): The method according to claim 21, wherein the injection is an intra-tumoral injection.

Claim 25 (new): The method according to claim 13, wherein the antigen is a tumor-specific antigen.

Claim 26 (new): The method according to claim 13, wherein the antigen is an antigen of human papilloma virus (HPV) or adenovirus.